Innovators for Animals: Sunil Narisetty
Learn more about our Vice President of Development Sciences and Technologies, his passion for animal health, and his role in treating osteoarthritis pain in cats.
Sunil Narisetty, Vice President of Development Sciences and Technologies, VMRD at Zoetis, expresses his passion for working in science and animal health transforming molecules into amazing medicines that advance care for animals. Recognizing the significant unmet need in cat pain management, Sunil discusses the development of Solensia®, a Monoclonal Antibody treatment designed to treat chronic osteoarthritis pain in cats. For the future, Sunil looks forward to exploring the tremendous opportunity Monoclonal Antibody technology poses to create novel therapies in additional unmet need areas.
SOLENSIA IMPORTANT SAFETY INFORMATION: See full Prescribing Information. For use in cats only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Solensia should not be used in breeding cats or in pregnant or lactating queens. Solensia should not be administered to cats with known hypersensitivity to frunevetmab. The most common adverse events reported in a clinical study were vomiting and injection site pain.
LIBRELA IMPORTANT SAFETY INFORMATION: See full Prescribing Information. For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. LIBRELA should not be used in breeding dogs or in pregnant or lactating dogs. LIBRELA should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis.
CYTOPOINT INDICATION: Cytopoint has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.
APOQUEL INDICATION: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
APOQUEL IMPORTANT SAFETY INFORMATION: Do not use Apoquel in dogs less than 12 months of age or those with serious infections. Apoquel may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. Apoquel has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel has been used safely with many common medications including parasiticides, antibiotics and vaccines. See the full Prescribing Information.
